SCHEMBL715774

SCHEMBL715774

CC(C)(C)OC(=O)N1C[C@@H](O)CC[C@H]1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.43
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
NR1H2 P55055 1/20 0.36
HPGD P15428 1/20 0.35
BTK Q06187 1/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17812940 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL6998193 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL24829907 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL16857497 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL19566139 0.87 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL17812928 0.87 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL16187270 0.87 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL715773 0.87 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL13066371 0.87 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10CYP2C19
SCHEMBL16857337 0.86 CHRM2 (0.44) CHRM2CHRM1CHRM3HSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3854786-B1 METHOD FOR PRODUCING AMINO ACID DERIVATIVES UBE CORP (JP) 2026-02-18 EP disclosed
US-20250205167-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES, INC. 2025-06-26 US disclosed
US-20250179542-A1 BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS CODEXIS INC (US) 2025-06-05 US disclosed
US-12281074-B2 Method for producing amino acid derivatives UBE CORPORATION (JP) 2025-04-22 US disclosed
CN-119707784-A Process for preparing amino acid derivatives 株式会社API 2025-03-28 CN disclosed
US-12247234-B2 Biocatalysts and methods for hydroxylation of chemical compounds CODEXIS, INC. (US) 2025-03-11 US disclosed
EP-4499607-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2025-02-05 EP disclosed
US-12202800-B2 Method for producing amino acid derivatives API CORPORATION (JP) 2025-01-21 US disclosed
CN-112930338-B Process for preparing amino acid derivatives 株式会社API 2024-12-24 CN disclosed
CN-119072464-A Novel ionizable lipids and lipid nanoparticles and methods of use thereof 赛欧生物医药股份有限公司 2024-12-03 CN disclosed
US-10370688-B2 Methods for hydroxylyation of chemical compounds CODEXIS, INC. (US) 2019-08-06 US disclosed
EP-2847327-B1 BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS CODEXIS INC (US) 2018-12-26 EP disclosed
EP-2889288-B1 METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID API CORP (JP) 2018-07-25 EP disclosed
US-9981984-B2 Method for producing cis-5-hydroxy-2-piperidinecarboxylic acid derivative, and method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid API CORPORATION (JP) 2018-05-29 US disclosed
US-9790527-B2 Engineered proline hydroxylase polypeptides CODEXIS, INC. (US) 2017-10-17 US disclosed
US-20170121744-A1 BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2017-05-04 US disclosed
US-20150239906-A1 Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid UBE CORPORATION (JP) 2015-08-27 US disclosed
EP-2889288-A1 METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID API Corporation (JP) 2015-07-01 EP disclosed
US-20150118719-A1 BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2015-04-30 US disclosed
US-20120053350-A1 PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS MERCK SHARP & DOHME CORP. 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205167-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME PHOSPHO1, SGMS2, SGMS1 CHRM2 4417/4885CHRM1 4686/4885CHRM3 4044/4885
US-20150239906-A1 Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid HCAR2, HCAR1, C5 CHRM2 1238/4885CHRM1 880/4885CHRM3 3174/4885
US-20120053350-A1 PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS SULT1A1, SULT1E1, PGD CHRM2 835/4885CHRM1 215/4885CHRM3 1026/4885
US-12202800-B2 Method for producing amino acid derivatives GLO1, BCAT2, BCAT1 CHRM2 3692/4885CHRM1 2310/4885CHRM3 4182/4885
US-12281074-B2 Method for producing amino acid derivatives PTGS2, PTGES, PTGES2 CHRM2 3317/4885CHRM1 3092/4885CHRM3 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.